Memantine ER/Donepezil: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) Create Namzaric combo scaffold |
MDElliottMD (talk | contribs) Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved. |
||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
| classes = Combined cholinesterase inhibitor + NMDA antagonist | | classes = Combined cholinesterase inhibitor + NMDA antagonist | ||
| uses = <vote slug="alzheimers-use">Moderate-to-severe Alzheimer's dementia</vote> | | uses = <vote slug="alzheimers-use">Moderate-to-severe Alzheimer's dementia</vote> | ||
| starting_dose = For patients already stable on memantine 28 mg/d + donepezil 10 mg/d | | starting_dose = For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength | ||
| preparations = 7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) | | preparations = 7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) | ||
| fda_max = 28/10 mg/d | | fda_max = 28/10 mg/d | ||
| Line 12: | Line 12: | ||
| halflife = ~60–80 h (memantine); ~70 h (donepezil) | | halflife = ~60–80 h (memantine); ~70 h (donepezil) | ||
| bioavailability = ~100% both components | | bioavailability = ~100% both components | ||
| pregnancy = Not relevant (geriatric | | pregnancy = Not relevant (geriatric problem) | ||
| legal = Rx-only in US | | legal = Rx-only in US | ||
| mechanism = Donepezil: reversible AChE inhibitor | | mechanism = Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. | ||
| intro = Namzaric is a once-daily fixed-dose combination of memantine ER and donepezil, for patients with moderate-to-severe Alzheimer's already stable on both components. The convenience is real | | intro = Namzaric is a once-daily fixed-dose combination of memantine ER and donepezil, for patients with moderate-to-severe Alzheimer's already stable on both components. The convenience is real, daily pill burden cut roughly in half. The trade-off is reduced ability to titrate each component independently. | ||
| indications = | | indications = | ||
| dosing = | | dosing = | ||